• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Siddiqui on first-line treatments for bladder cancer

Video

“This category of therapeutic is fairly well-tolerated; safe to give,” says Mohummad M. Siddiqui MD.

In this video, Mohummad M. Siddiqui, MD, discusses the main takeaways concerning the bladder cancer therapeutics durvalumab (Imfinzi)/atezolizumab (Tecentriq) and pembrolizumab (Keytruda)/atezolizumab, which were topics focused on during the bladder cancer course presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Siddiqui is an associate professor of surgery and director of urologic oncology and robotic surgery at the University of Maryland, Baltimore.

Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.